Overview

* Elutia ( ELUT ) Q3 revenue missed analyst expectations

* Company completed $88 mln sale of BioEnvelope business to Boston Scientific

* Gross margin improved to 55.8% from 48.9% in Q3 2024

Outlook

* Elutia ( ELUT ) anticipates FDA clearance for NXT-41x base matrix in 2H26

* Company expects drug-eluting NXT-41x version clearance in 1H27

Result Drivers

* BIOENVELOPE SALE - Sale of BioEnvelope business to Boston Scientific for $88 mln used to eliminate debt and fund NXT-41x development

* NXT-41X DEVELOPMENT - Advancing NXT-41x to address infections in plastic and reconstructive surgery, targeting a $1.5 bln market

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $3.32 $6.65

Revenue mln mln (2

Analysts

)

Q3 Net -$3.87

Income mln

Q3 Gross $1.85

Profit mln

Q3 -$5.21

Income mln

From

Operatio

ns

Q3 $7.06

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Elutia Inc ( ELUT ) is $4.00, about 76% above its November 5 closing price of $0.96

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)